

Jarl Ulf Jungnelius resigns from Oncopeptides' Board of Directors

Stockholm, February 5, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that Jarl Ulf Jungnelius has informed the Board of Directors of his decision to step down from the Board of Directors of Oncopeptides in which he has served since 2011. This due to personal reasons related to a change of domicile from Sweden.

“With his extensive oncology experience Ulf has made important contributions to Oncopeptides, particularly during the development phase of Pepaxti,” says Per Wold-Olsen, Chairman of the Board at Oncopeptides. “We wish Ulf the best of luck in the future and thank him for his 14 years of service to the company”.

For more information, please contact:

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)

E-mail: david.augustsson@oncopeptides.com

Cell phone: +46 76 229 38 68

About Oncopeptides

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug, Pepaxti, is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com

Attachments

[Jarl Ulf Jungnelius resigns from Oncopeptides' Board of Directors](#)